Arf6, RalA, and BIRC5 protein expression in nonsmall cell lung cancer

Knizhnik, A. V.; Ковалева, О. В.; Лактионов, К. К.; Мочальникова, В В; Komelkov, A. V.; Tchevkina, Elena M.; Zborovskaya, I. B.

doi:10.1134/s0026893310061032

Cited by 20 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies, including tissue expression studies, animal models and clinical trials, have investigated BIRC5/survivin polymorphisms and cancer risk. The results of these studies suggested that BIRC5/survivin plays a significant role in carcinogenesis (1,4). The present study confirmed that genetic susceptibility in miRNA binding regions contributes to altered gene function.…”

Section: Discussionsupporting

confidence: 83%

“…Previous studies have demonstrated that survivin, unlike other IAPs, is strongly expressed in the majority of neoplasms. Overexpression of survivin is also significantly correlated with a poor prognosis and decreased survival rates in breast and lung cancer, colon, bladder and Ewing sarcoma, and lymphomas (2)(3)(4)(5)(6)(7). BIRC5/survivin is an essential protein involved in Ewing sarcoma cell growth and proliferation (7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between functional variants in BIRC5/survivin gene 3′ untranslated region and mRNA expression in lymphoblastoid cell lines

Shao

Yang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Association between functional variants in BIRC5/survivin gene 3′ untranslated region and mRNA expression in lymphoblastoid cell lines

Shao

Yang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

“…The results from Co‐IP assay further demonstrated that RCC2 could interact with RalA, and RCC2 and RalA could also form a stable complex. In fact, decreased RalA expression suppressed regional metastasis in squamous cell lung cancer (45). These results further demonstrated that up‐regulation of RalA by RCC2 plays an important role in ovarian cancer progression.…”

Section: Discussionmentioning

confidence: 99%

RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin‐resistant ovarian cancer

et al. 2019

View full text Add to dashboard Cite

Currently, cisplatin (DDP) is the first‐line chemotherapeutic agent used for treatment of ovarian cancer, but gradually acquired drug resistance minimizes its therapeutic outcomes. We aimed to identify crucial genes associated with DDP resistance in ovarian cancer and uncover potential mechanisms. Two sets of gene expression data were downloaded from Gene Expression Omnibus, and bioinformatics analysis was conducted. In our study, the differentially expressed genes between DDP‐sensitive and DDP‐resistant ovarian cancer were screened in GSE15709 and GSE51373 database, and chromosome condensation 2 regulator (RCC2) and nucleoporin 160 were identified as 2 genes that significantly up‐regulated in DDP‐resistant ovarian cancer cell lines compared with DDP‐sensitive cell lines. Moreover, RCC2, Ral small GTPase (RalA), and Ral binding protein‐1 (RalBP1) expression was found to be significantly higher in DDP‐resistant ovarian cancer tissues than in DDP‐sensitive tissues. RCC2 plays a positive role in cell proliferation, apoptosis, and migration in DDP‐resistant ovarian cancer cell lines in vitro and in vivo. Furthermore, RCC2 could interact with RalA, thus promoting its downstream effector RalBP1. RalA knockdown could reverse the effects of RCC2 overexpression on DDP‐resistant ovarian cancer cell proliferation, apoptosis, and migration. Similarly, RalA overexpression could alleviate the effects of RCC2 knockdown in DDP‐resistant ovarian cancer cells. Taken together, RCC2 may function as an oncogene, regulating the RalA signaling pathway, and intervention of RCC2 expression might be a promising therapeutic strategy for DDP‐resistant ovarian cancer. —Gong, S., Chen, Y., Meng, F., Zhang, Y., Wu, H., Li, C., Zhang, G. RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin‐resistant ovarian cancer. FASEB J. 33, 5350–5365 (2019). http://www.fasebj.org

show abstract

“…A recent study examined the expression levels of RalA in lung cancer and reported 0169-5002/$ -see front matter © 2012 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.lungcan.2012.03.007 decreased RalA protein expression in comparison to normal tissue samples in 64% of non-small cell lung cancer regardless to morphological structure [12]. Also, a correlation between decrease in RalA expression and absence of regional metastases was revealed for squamous cell lung cancer [12].…”

Section: Introductionmentioning

confidence: 86%